Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress Life Science Investing
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones Life Science Investing
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City Life Science Investing
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 Life Science Investing
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue Life Science Investing
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases Life Science Investing
